Targeting Proteins and Proteolysis to counter Cancer
Covered in this webinar:
PROTAC is a hetero bifunctional molecule promoting protein of interest (POI) ubiquitination by forming a ternary complex with an E3 ligase. The use of PROTACs is a promising and highly appealing technology, any new approach demands a lot of effort to develop the ternary complex with the best affinity. More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications.
This webinar covers keys aspects of PROTAC technology approaches implemented in order to develop new anticancer drugs
Main topics :
- How PROTAC technology can overcome on-target toxicity of anticancer agents
- Structure-based design approaches for developing PROTACs against cancer
Watch your on demand webinar
Aileen frost, PhD
Alessio Ciulli Research Group
Medicinal Chemist and Organic Chemistry Scientist
Biological Chemistry and Drug Discovery,School of Life Sciences University of Dunde
Daohong Zhou, PhD
Professor of Pharmacodynamics and Radiation Oncology
Harry E. Innes Endowed Professor of Cancer Research
Associate Director for Translation and Drug Development
University of Florida Health Cancer Center University of Florida at Gainesville
Cancer drug development tends to focus on inhibiting protein activity rather than modulating protein levels. While this approach has seen some success, it does come with challenges, such as long-term resistance and toxicity. Targeted protein degradation offers a potential solution to this problem.
Protein degraders are small molecules that induce degradation and remove deleterious proteins from afflicted cells by modulating E3 ligase ubiquitination activity. In this webinar, brought to you by The Scientist and sponsored by Revvity, researchers will discuss how small-molecule degraders work, key points of interest in their design, and their applications in both the laboratory and the clinic.